VRP Verona Pharma Plc

 
TIDMVRP 
 
   LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona 
Pharma plc (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage 
biopharmaceutical company focused on respiratory diseases, announces 
that David Zaccardelli, Chief Executive Officer and President, will 
present a company overview at the following virtual investor conferences 
in November 2020: 
 
   Stifel 2020 Virtual Healthcare Conference 
 
   Date: Monday, November 16 
 
   Time: 4:00 PM ET / 9:00 PM GMT 
 
   Jefferies Virtual London Healthcare Conference 
 
   Date: Tuesday, November 17 
 
   Time: 10:50 AM ET / 3:50 PM GMT 
 
   Live webcasts of the events will be available on the Events and 
Presentations link on the Investors page of the Company's website, 
https://www.globenewswire.com/Tracker?data=0qkm81GPXXWI7MSKd6VGFD1WrEhafHkluVUjVhUXfz1R6HqhNS5Zxg68SihmvVeIkEWa5s_ePcn9UVmv_gOMl23WOCnuu-Z_nYMmfsVFuNA= 
www.veronapharma.com, and an audio replay will be available there for 30 
days. 
 
 
 
 
  Verona Pharma plc                           Tel: +44 (0)20 3283 4200 
  Victoria Stewart, Director of               mailto:info@veronapharma.com info@veronapharma.com 
  Communications 
                                            ----------------------------------------------------------- 
 
  Argot Partners                              Tel: +1 212-600-1902 
   (US Investor Enquiries)                     mailto:verona@argotpartners.com verona@argotpartners.com 
                                            ----------------------------------------------------------- 
  Kimberly Minarovich / Michael Barron 
 
  Optimum Strategic Communications            Tel: +44 (0)20 950 9144 
   (European Media and Investor Enquiries)     verona@optimumcomms.com 
  Mary Clark / Eva Haas / Shabnam Bashir 
------------------------------------------  ----------------------------------------------------------- 
 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. The Company is evaluating 
nebulized ensifentrine in its Phase 3 clinical program ENHANCE 
("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD 
maintenance treatment. The Company raised gross proceeds of $200 million 
through a private placement in July 2020 and expects the funds to 
support its operations and Phase 3 clinical program into 2023. Two 
additional formulations of ensifentrine are currently in Phase 2 
development for the treatment of COPD: dry powder inhaler ("DPI") and 
pressurized metered-dose inhaler ("pMDI"). Ensifentrine is being 
evaluated in a pilot clinical study in patients hospitalized with 
COVID-19 and has potential applications in cystic fibrosis, asthma and 
other respiratory diseases. For more information, please visit 
https://www.globenewswire.com/Tracker?data=0qkm81GPXXWI7MSKd6VGFM-RLgp-Kqw4xITCX17KVbNoiRLQX19m-aY1gibAxsGFg3r5piHIJD6aQngw8AI2Rr-EKPUVDzbOoAMiOTCE3o0= 
www.veronapharma.com. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements. These 
forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements. Any such forward-looking statements 
represent management's estimates as of the date of this press release. 
While we may elect to update such forward-looking statements at some 
point in the future, we disclaim any obligation to do so, even if 
subsequent events cause our views to change. These forward-looking 
statements should not be relied upon as representing our views as of any 
date subsequent to the date of this press release. 
 
 
 
 

(END) Dow Jones Newswires

November 09, 2020 02:00 ET (07:00 GMT)

Verona Pharma (LSE:VRP)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Verona Pharma (LSE:VRP)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024